The European Union Good Manufacturing Practice (EU-GMP) authorities have conducted their first inspection at Concord Biotech’s Active Pharmaceutical Ingredients (API) manufacturing facility located at Limbassi. The inspection was carried out from August 18, 2025 to August 21, 2025. 

This milestone marks a significant achievement for Concord, as a successful EU-GMP inspection not only validates its commitment to global quality standards but also paves the way for expanding its footprint into new international markets. The approval will enable Concord to explore commercial opportunities across various EU territories and other regulated geographies, strengthening its global presence and growth trajectory.

This milestone reaffirms the company’s commitment to the highest standards of quality, safety, and regulatory compliance, reflecting its dedication to operational excellence and alignment with global regulatory expectations.

Concord Biotech is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across Immunosuppressants and oncology.